This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Malaria; <i>Salmonella</i>	Heme oxygenase decycling 1 (HMOX1; HO-1; Hsp32)	<p>Mouse studies suggest inhibiting HO-1 could protect against <i>Salmonella</i> infection in patients exposed to malaria. In a mouse model of <i>Salmonella</i> infection, animals previously exposed to malaria had greater bacteremia and lower survival than unexposed mice. In previously exposed mice, an HO-1 inhibitor given prior to <i>Salmonella</i> infection decreased bacteremia and increased survival compared with no treatment. Next steps include evaluating an HO-1 inhibitor in additional models of malaria-<i>Salmonella</i> co-infection. OB-24, an HO-1 inhibitor from Osta Biotechnologies Inc., is in preclinical development for prostate cancer. SyB-0702, a polyethylene glycol-conjugated zinc protoporphyrin (PEG-ZnPP) that targets HO-1 from SymBio Pharmaceuticals Ltd., is in preclinical development for solid tumors.</p> <p>SciBX 5(1); doi:10.1038/scibx.2012.19 Published online Jan. 5, 2012</p>	Unpatented; unavailable for licensing	<p>Cunnington, A.J. <i>et al. Nat. Med.</i>; published online Dec. 18, 2011; doi:10.1038/nm.2601</p> <p>Contact: Eleanor M. Riley, London School of Hygiene & Tropical Medicine, London, U.K. e-mail: eleanor.riley@lshtm.ac.uk</p>